Table 1. . Studies evaluating androgen deprivation therapy in men with prostate cancer.

Study (year)	Study type	Summary of findings	Ref.
Basaria et al. (2006)	Cross-sectional study	Long-term ADT may increase risk of developing insulin resistance and hyperglycemia in men with prostate cancer	[16]
Braga-Basaria et al. (2006)	Cross-sectional study	Long-term ADT is associated with insulin resistance, lipid alterations and abdominal obesity	[17]
Smith et al. (2002)	Prospective study	Treatment with ADT can lead to increase in weight, fat body mass and decrease in lean body mass in men with nonmetastatic prostate cancer	[19]
Smith et al. (2006)	Prospective study	Insulin sensitivity decreased with short-term ADT in men with locally advanced or recurrent metastatic prostate cancer	[20]

ADT: Androgen-deprivation therapy.